RM LAW, P.C. is investigating potential claims against the board of directors of Cascadian Therapeutics, Inc. (“Cascadian Therapeutics” or the “Company”) (NASDAQ: CASC) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell the Company to Seattle Genetics, Inc. in a transaction valued at approximately $614 million.
If you own shares of Cascadian Therapeutics and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here. You may also email Mr. Maniskas at firstname.lastname@example.org.
Under the terms of the agreement, shareholders of Cascadian Therapeutics will receive $10.00 in cash for each share of Cascadian Therapeutics common stock.
Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cascadian Therapeutics or not acting in the Company’s shareholders’ best interests in connection with the sale process.